Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: A potential therapeutic target

Modern Pathology

Volumn 21, Issue 12, 2008, Pages 1527-1532

  Bohling, Sandra D ^a   Allison, Kimberly H ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Breast carcinoma; FoxP3; Prognostic indicators; Regulatory T cells

Indexed keywords

ANTIBODY; ESTROGEN RECEPTOR ANTIBODY; FOXP3 ANTIBODY; HER2 ANTIBODY; HORMONE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; EPITHELIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; LYMPH NODE METASTASIS; NEEDLE BIOPSY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; TUMOR VOLUME;

BREAST NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 56649102194     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.160     Document Type: Article

References (41)

1. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-336.
2. Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006;212:8-27.
3. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004;4:408-414.
4. Lund JM, Hsing L, Pham TT, et al. Coordination of early protective immunity to viral infection by regulatory T Cells. Science 2008;320:1168-1169.
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061.
6. Le NT, Chao N. Regulating regulatory T cells. Bone Marrow Transplant 2007;39:1-9.
7. Dunbar PR, Smith CL, Chao D, et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune response. J Immunol 2000;165:6644-6652.
8. Lee PP, Yee C, Savage PA, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685.
9. Romero P, Dunbar PR, Valmori D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-1650.
10. Salio M, Shepherd D, Dunbar PR, et al. Mature dendritic cells prime functionally superior melan-A-specific CD8+ lymphocytes as compared with nonprofessional APC. J Immunol 2001;167:1188-1197.
11. Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003;9:562-567.
12. Bach JF. Regulatory T cells under scrutiny. Nat Rev Immunol 2003;3:189-198.
13. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
14. Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4(+)CD25(+) Tcells with regulatory properties from human blood. J Exp Med 2001;193:1303-1310.
15. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-1302.
16. Ng WF, Duggan PJ, Ponchel F, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001;98:2736-2744.
17. Read S, Powrie F. CD4(+) regulatory T cells. Curr Opin Immunol 2001;13:644-649.
18. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389-400.
19. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat Rev Immunol 2003;3:223-232.
20. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199-210.
21. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-5380.
22. Ichihara F, Kono K, Takahashi A, et al. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 2003;9:4404-4408.
23. Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004;173:1444-1453.
24. Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 2008;8:57.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
26. Woo YL, Sterling JC, Crawford RA, et al. FOXP3 immunohistochemistry on formalin-fixed paraffin embedded tissue- poor correlation between different antibodies. J Clin Pathol 2008;61:969-971.
27. Roncador G, Brown PJ, Maestre L, et al. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. Eur J Immunol 2005;35:1681-1691.
28. Gilchrist KW, Gray R, Fowble B, et al. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients. J Clin Oncol 1993;11:1929-1935.
29. Langlands AO, Pocock SJ, Kerr GR, et al. Long-term survival of patients with breast cancer: a study of the curability of the disease. Br Med J 1979;2:1247-1251.
30. Toikkanen SP, Kujari HP, Joensuu H. Factors predicting late mortality from breast cancer. Eur J Cancer 1991;27:586-591.
31. Ladoire S, Arnould L, Apetoh L, et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells. Clin Cancer Res 2008;14:2413-2420.
32. Zuo T, Liu R, Zhang H, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007;117:3765-3773.
33. Mizukami Y, Kono K, Kawaguchi Y, et al. Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 2008;98:148-153.
34. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218.
35. Steitz J, Bruck J, Lenz J, et al. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001;61:8643-8646.
36. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001;194:823-832.
37. Tanaka H, Tanaka J, Kjaergaard J, et al. Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002;25:207-217.
38. Knutson KL, Dang Y, Lu H, et al. IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 2006;177:84-91.
39. Foss FM. DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000;1:110-116.
40. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167-1174.
41. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-6053.